logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience further enhances drug delivery platform as human tests show it delivers THC within 10 minutes

It was tested in pilot human tests using edibles and this enhanced version is around twice as fast as traditional DehydraTECH

Lexaria Bioscience Corp -
Further testing and evaluation will now be carried out before these improvements will be released to Lexaria technology licensees, the firm said

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) announced Thursday a further improvement to its innovative DehydraTECH drug platform, reporting it can now deliver the action of THC (tetrahydrocannabinol) to people in less than ten minutes. 

It was tested in pilot human tests using edibles, and this enhanced version is around twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations, the firm said.

Further testing and evaluation will now be carried out before these improvements will be released to Lexaria technology licensees, expected near the second quarter of 2020.

READ: Lexaria Bioscience closes US$700,000 financing to fund research into DehydraTECH

"Oral delivery of THC within 10 minutes offers significant advantages for both medical and adult use applications where rapid onset is highly desirable in response to certain conditions such as pain or seizures. Generic cannabis edibles often require 90 to 120 minutes after ingestion before there are perceptible effects of THC," Lexaria said in a statement.

Today's announcement marks the latest improvement to the drug delivery platform and was completed with human volunteers and with THC rather than with CBD as was used in earlier animal studies.

On June 4 this year, the company announced that DehydraTECH innovations had demonstrated through a series of animal studies an ability to deliver 811% more CBD into blood, and up to 1,937% more into brain tissue, both compared to generic industry MCT formulations.

The firm's patented DehydraTECH system changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules.

Lexaria has 16 patents granted and over 60 patents pending worldwide.

Shares nudged up 1.35% in Toronto to stand at C$0.47 each.

Quick facts: Lexaria Bioscience Corp.

Price: 0.53 CAD

CSE:LXX
Market: CSE
Market Cap: $41.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Market conditions worsen for cannabis companies but Canntab...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada sank 3.7% to 141.07 points. The OTCQX Cannabis Index slipped 2.6% to 515.3 points. Buds today were Canntab Therapeutics Limited (CSE:PILL) (OTCMKTS:CTABF), Lexaria Bioscience Corp (CSE:LXX)...

on 8/10/19

2 min read